Mega Lifesciences Public Company Limited

SET:MEGA Stock Report

Market Cap: ฿29.9b

Mega Lifesciences Past Earnings Performance

Past criteria checks 4/6

Mega Lifesciences has been growing earnings at an average annual rate of 1%, while the Pharmaceuticals industry saw earnings growing at 8.1% annually. Revenues have been growing at an average rate of 0.9% per year. Mega Lifesciences's return on equity is 19.7%, and it has net margins of 14.1%.

Key information

1.00%

Earnings growth rate

0.98%

EPS growth rate

Pharmaceuticals Industry Growth12.39%
Revenue growth rate0.94%
Return on equity19.67%
Net Margin14.13%
Next Earnings Update13 Aug 2026

Recent past performance updates

Recent updates

Narrative Update • Jun 07

MEGA: Stable Assumptions And Margin Outlook Will Drive Future Upside

Analysts have kept their price target for Mega Lifesciences unchanged at THB 41.14, citing only small adjustments to projected revenue growth, profit margins and future P/E assumptions that do not materially alter their overall view of the stock. What's in the News No recent company specific news for Mega Lifesciences has been provided in the available sources.
Narrative Update • May 24

MEGA: Higher Margin Outlook And Dividend Decision Will Support Future Upside

Analysts have trimmed their price target for Mega Lifesciences slightly to THB 41.14 from THB 41.17, reflecting updated assumptions that now pair a lower revenue growth outlook of 4.12% with a higher projected profit margin of 16.40% and a modestly lower future P/E of 16.67x. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).
Narrative Update • May 06

MEGA: Stable Outlook And Upcoming Dividend Decision Will Drive Further Upside

Analysts have kept their fair value estimate for Mega Lifesciences steady at THB41.17 per share, with only minimal model tweaks related to the discount rate, profit margin outlook and future P/E assumptions. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).
Narrative Update • Apr 21

MEGA: Higher Growth And Lower Margins Will Likely Keep Shares Fairly Valued

Analysts have lifted their price target on Mega Lifesciences from THB 32 to THB 35, citing updated assumptions around higher revenue growth, a slightly lower discount rate and a revised future P/E multiple, partially offset by a more conservative profit margin outlook. What's in the News Board meeting scheduled for Feb 24, 2026, to consider a dividend payment proposal for the year ended Dec 31, 2025 (company filing).
Narrative Update • Apr 06

MEGA: Stable Outlook And Upcoming Dividend Decision Will Support Upside

Analysts have maintained their price target for Mega Lifesciences at THB41.17, citing unchanged assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).
Narrative Update • Mar 23

MEGA: Higher Fair Value And Upcoming Dividend Decision Will Support Upside

Analysts have lifted their fair value estimate for Mega Lifesciences from THB 38.21 to THB 41.17, citing updated assumptions for long term profit margins and a higher future P/E multiple. What's in the News A board meeting is scheduled for February 24, 2026 for Mega Lifesciences Public Company Limited.
Narrative Update • Mar 09

MEGA: Higher Future P/E Will Support Upgraded Fair Value Outlook

Analysts have lifted their price target for Mega Lifesciences from THB 41.60 to THB 45.00. They highlighted updated assumptions that include slightly lower revenue growth and profit margins, together with a higher future P/E multiple.
Narrative Update • Feb 23

MEGA: Updated Discount Rate And Margins Will Support Fair Pricing Ahead

Analysts have raised their price target on Mega Lifesciences to THB 38.21 from THB 34.58, citing updated assumptions related to slightly lower discount rates, adjusted revenue growth, modestly different profit margins and a revised future P/E multiple. Valuation Changes Fair Value: THB 34.58 to THB 38.21, indicating a modest uplift in the assessed share valuation.
Narrative Update • Feb 09

MEGA: Fair Outlook Will Balance Softer Margins With Stronger Revenue Expectations

Narrative update on Mega Lifesciences The analyst price target for Mega Lifesciences has been lifted from ฿39.00 to ฿41.60, with analysts linking this change to updated assumptions for slightly lower discount rates, higher forecast revenue growth, a modestly softer profit margin, and a higher future P/E multiple. Valuation Changes Fair Value Estimate: Raised from THB 39.00 to THB 41.60, a small uplift in the assessed equity value.
Narrative Update • Jan 25

MEGA: Stable Assumptions And Margins Will Support Fair Pricing Ahead

The analyst price target for Mega Lifesciences remains unchanged at ฿34.58, with analysts citing consistent assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Valuation Changes Fair value: Unchanged at THB34.58 per share, with no adjustment to the underlying assumptions.
Narrative Update • Jan 10

MEGA: Higher Margin Assumptions Will Likely Leave Shares Overvalued

The analyst fair value estimate for Mega Lifesciences has been adjusted from ฿26.00 to ฿32.00, with analysts pointing to updated assumptions around revenue growth, profit margins and forward P/E to support the higher target. Valuation Changes The fair value estimate has risen from THB 26.00 to THB 32.00 per share, reflecting updated assumptions in the model.
Narrative Update • Dec 24

MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead

Analysts have reaffirmed their price target on Mega Lifesciences at THB 34.58 per share, citing unchanged assumptions for discount rate, revenue growth, profit margins, and future valuation multiples, which together support a steady outlook for the company’s fair value. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the overall equity valuation.
Narrative Update • Dec 09

MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead

Analysts have maintained their price target on Mega Lifesciences at THB 34.58 per share, reflecting steady assumptions on revenue growth, profit margins, and valuation multiples despite the latest review of fundamentals. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the core valuation thesis.
Narrative Update • Nov 25

MEGA: Improved Profit Margins And Revenue Estimates Suggest Fair Valuation Ahead

Analysts have raised their price target for Mega Lifesciences from THB 32.14 to THB 34.58. This reflects improved revenue growth forecasts and a slightly stronger profit margin outlook.
User avatar
New Narrative • Jun 01

Expansion In Indonesia And Vietnam Will Fuel Emerging Wellness Markets

Strategic expansion in high-growth markets and local manufacturing reduce operational risks and support sustainable revenue and margin growth.

Revenue & Expenses Breakdown

How Mega Lifesciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SET:MEGA Revenue, expenses and earnings (THB Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2614,6282,0674,5420
31 Dec 2514,1951,9124,4810
30 Sep 2514,1911,9744,3860
30 Jun 2514,3121,8634,3830
31 Mar 2514,8591,9854,3820
31 Dec 2415,3852,0124,3850
30 Sep 2415,8821,8464,4100
30 Jun 2415,6851,9994,3310
31 Mar 2415,7182,0174,2300
31 Dec 2315,7161,9934,1910
30 Sep 2315,4421,9194,2780
30 Jun 2315,6932,0424,3520
31 Mar 2315,6342,0814,3980
31 Dec 2215,7272,2424,3590
30 Sep 2215,1162,3384,0680
30 Jun 2215,0612,2924,0540
31 Mar 2214,7242,2273,9240
31 Dec 2114,1721,9473,7690
30 Sep 2114,3951,8783,7670
30 Jun 2113,7751,6073,5380
31 Mar 2112,8091,4063,3310
31 Dec 2012,6131,3933,2880
30 Sep 2012,1681,3483,1690
30 Jun 2011,6421,2883,1370
31 Mar 2011,6551,2053,1950
31 Dec 1911,1641,1393,1760
30 Sep 1910,9501,1633,1980
30 Jun 1910,7121,1363,1530
31 Mar 1910,5691,2033,1130
31 Dec 1810,2841,2063,0520
30 Sep 1810,1471,1833,0410
30 Jun 189,9371,1753,0100
31 Mar 189,8291,1782,9880
31 Dec 179,6241,1132,9650
30 Sep 179,5141,0232,9280
30 Jun 179,2829452,8690
31 Mar 178,9688732,7660
31 Dec 168,8287952,6740
30 Sep 168,5147712,6030
30 Jun 168,2267562,6580
31 Mar 168,1157032,7140
31 Dec 157,9666962,7180
30 Sep 157,7756752,6680
30 Jun 157,8626342,5800

Quality Earnings: MEGA has high quality earnings.

Growing Profit Margin: MEGA's current net profit margins (14.1%) are higher than last year (13.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MEGA's earnings have grown by 1% per year over the past 5 years.

Accelerating Growth: MEGA's earnings growth over the past year (4.1%) exceeds its 5-year average (1% per year).

Earnings vs Industry: MEGA earnings growth over the past year (4.1%) did not outperform the Pharmaceuticals industry 8.8%.

Return on Equity

High ROE: MEGA's Return on Equity (19.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 00:13
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mega Lifesciences Public Company Limited is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thanapol JiratanakijCGS International
Chanpen SirithanarattanakulDBS Bank Ltd
Nantika WiangphoemDBS Bank Ltd